Conference Reports for NATAP

Back

Digestive Disease Week 02nd - 05th June 2018 Washington, D.C     Validation of a low cost, point of care screening device for HCV antibody detection in low resource peri-urban settings of Karachi, Pakistan - (06/19/18)   Sofosbuvir + Glecaprevir/Pibrentasvir (G/P) in patients with difficult to treat HCV infection. Final results of the French compassionate use - (06/19/18)   PATTERNS OF DRUG AND ALCOHOL USE AND INJECTION RISK BEHAVIOURS AMONG PEOPLE WHO INJECT DRUGS DURING AND FOLLOWING HCV DIRECT-ACTING ANTIVIRAL TREATMENT: INSIGHTS FROM TRAJECTORY ANALYSES - (06/19/18)   A Comparison of Insurance Approval Rates and Economic Disparity for Ledipasvir/Sofosbuvir Based Hepatitis C Therapy Versus Velpatasvir/Sofosbuvir in a Single Urban Center - (06/19/18)   Access to and Utilization of Sofosbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network - (06/18/18)   SOF/VEL/VOX for 12 Weeks is a Safe and Effective Salvage Regimen for NS5A Inhibitor-Experienced Patients with Genotype 1-6 HCV Infection: An Integrated Analysis of Phase 2 and Phase 3 Studies - (06/18/18)   Emergence and Long-term Persistence of NS3, NS5A, and NS5B Resistance Associated Substitutions After Treatment With Direct-acting Antivirals - (06/01/18)   Long-Term Follow-up of Patients with Chronic HCV and F2-F3 Fibrosis After Achieving SVR with DAA-Based Therapy: Results from the Gilead SVR Registry - (06/01/18)